Carles Aracil

Lleida, CT, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 27 publications

Hepatocellular carcinoma in non-cirrhotic liver: a prospective Spanish multicenter study.

Hepatocellular carcinoma in non-cirrhotic liver: a prospective Spanish multicenter study.

Journal: Revista espanola de enfermedades digestivas

Published: December 18, 2025

Erratum to 'Carvedilol vs. propranolol for the prevention of decompensation and mortality in patients with compensated and decompensated cirrhosis' [J Hepatol 83 (2025) 70-80].

Erratum to 'Carvedilol vs. propranolol for the prevention of decompensation and mortality in patients with compensated and decompensated cirrhosis' [J Hepatol 83 (2025) 70-80].

Journal: Journal of hepatology

Published: September 06, 2025

Comprehensive immunophenotyping of gastric adenocarcinoma identifies an inflamed class of tumors amenable to immunotherapies.

Comprehensive immunophenotyping of gastric adenocarcinoma identifies an inflamed class of tumors amenable to immunotherapies.

Journal: Journal for immunotherapy of cancer

Published: February 22, 2025

Predicting Hepatic Decompensation in Patients With Metabolic Dysfunction Associated Steatotic Liver Disease-Related Cirrhosis: The ABID-LSM Model.

Predicting Hepatic Decompensation in Patients With Metabolic Dysfunction Associated Steatotic Liver Disease-Related Cirrhosis: The ABID-LSM Model.

Journal: Alimentary pharmacology & therapeutics

Published: January 20, 2025

Carvedilol vs. propranolol for the prevention of decompensation and mortality in patients with compensated and decompensated cirrhosis.

Carvedilol vs. propranolol for the prevention of decompensation and mortality in patients with compensated and decompensated cirrhosis.

Journal: Journal of hepatology

Published: August 07, 2024

Evolving epidemiology of HCC in Spain.

Evolving epidemiology of HCC in Spain.

Journal: JHEP reports : innovation in hepatology

Published: July 29, 2024

Hemodynamic effects of carvedilol plus simvastatin in cirrhosis with severe portal hypertension and suboptimal response to β-blockers: A double-blind, placebo-controlled, randomized trial.

Hemodynamic effects of carvedilol plus simvastatin in cirrhosis with severe portal hypertension and suboptimal response to β-blockers: A double-blind, placebo-controlled, randomized trial.

Journal: Hepatology (Baltimore, Md.)

Published: June 21, 2024

Progressive systemic inflammation precedes decompensation in compensated cirrhosis.

Progressive systemic inflammation precedes decompensation in compensated cirrhosis.

Journal: JHEP reports : innovation in hepatology

Published: January 21, 2024

Spontaneously ruptured hepatocellular carcinoma on non-cirrhotic liver: A prospective case series.

Spontaneously ruptured hepatocellular carcinoma on non-cirrhotic liver: A prospective case series.

Journal: Gastroenterologia y hepatologia

Published: June 14, 2023

Pre-emptive TIPS for the treatment of bleeding from gastric fundal varices: Results of a randomised controlled trial.

Pre-emptive TIPS for the treatment of bleeding from gastric fundal varices: Results of a randomised controlled trial.

Journal: JHEP reports : innovation in hepatology

Published: December 15, 2022

Metabolomics as a tool to predict the risk of decompensation or liver-related death in patients with compensated cirrhosis.

Metabolomics as a tool to predict the risk of decompensation or liver-related death in patients with compensated cirrhosis.

Journal: Hepatology (Baltimore, Md.)

Published: October 11, 2022

High frequency of acute decompensation and cancer in patients with compensated cirrhosis due to nonalcoholic fatty liver disease: A retrospective cohort study.

High frequency of acute decompensation and cancer in patients with compensated cirrhosis due to nonalcoholic fatty liver disease: A retrospective cohort study.

Journal: Hepatology communications

Published: April 10, 2022

Showing 1-12 of 27

Last Updated: 09/26/2026